Famotidine: Difference between revisions

At the start of the COVID-19 pandemic, some doctors observed that anecdotally some hospitalized patients on famotidine in China may have had better outcomes than other patients that were not taking famotidine. This led to hypotheses about use of famotidine in treament of COVID-19.<ref> {{cite magazine |url= https://www.science.org/content/article/new-york-clinical-trial-quietly-tests-heartburn-remedy-against-coronavirus |title= New York clinical trial quietly tests heartburn remedy against coronavirus | vauthors = Borrell B |date= 26 April 2020 |magazine = Science Magazine }} </ref><ref> {{cite journal | vauthors = Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang XP, White KM, Miorin L, Moreno E, Alon A, Delaforge E, Hennecker CD, Wang G, Pottel J, Blair RV, Roy CJ, Smith N, Hall JM, Tomera KM, Shapiro G, Mittermaier A, Kruse AC, García-Sastre A, Roth BL, Glasspool-Malone J, Ricke DO | display-authors = 6 | title = COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms | journal = Frontiers in Pharmacology | year = 20202021 | volume = 12 | pages = 633680 | pmid = 33833683 | pmc = 8021898 | doi = 10.212033389/rsfphar.32021.rs-30934/v2 633680| publicationdoi-dateaccess = 23 March 2021free }} </ref> Famotidine was researched for potential benefit in treating [[COVID-19]] following hypotheses at the start of the pandemic that it may be an applicable medication. No good evidence of benefit was found.<ref>{{cite journal | vauthors = Long B, Chavez S, Carius BM, Brady WJ, Liang SY, Koyfman A, Gottlieb M | title = Clinical update on COVID-19 for the emergency and critical care clinician: Medical management | journal = The American Journal of Emergency Medicine | volume = 56 | issue = | pages = 158–170 | date = June 2022 | pmid = 35397357 | pmc = 8956349 | doi = 10.1016/j.ajem.2022.03.036 | type = Review }}</ref>